News

The hedge fund management company earlier held a stake of 5.7% in the pharmaceutical firm, which develops and markets prescription and non-prescription products. Valeant’s main drug markets include

Allergan’s parent firm will be the parent of the combined new business. The company’s shareholders would receive 11.3 shares of the newly combined firm for each of their

Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous cells

A new £1bn fund will be used to support the global fight against malaria and other infectious diseases. The package includes £90m for the eradication of malaria implementation,

Kadmon has also licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market. Under the

In Europe, there are approximately 12,000 people with CF ages 12 and older who have two copies of this mutation. Vertex will now begin the country-by-country reimbursement approval

The company admitted that it gave rebates and patient referrals to specialty pharmacies for recommending both the drugs. Exjade is used to treat excess iron in blood, while

Invokamet XR is a once-daily fixed-dose combination of canagliflozin and metformin hydrochloride extended release (XR) in two tablets for glycemic control in type 2 diabetics. The FDA approved

BAX 826 is an investigational, extended half-life recombinant Factor VIII (rFVIII) candidate based on the full length ADVATE [Antihemophilic Factor (Recombinant)] molecule. Baxalta plans to enroll 30 patients